The inability of the FG-4497 treatment to protect against steatosis compared with the Hif-p4h-2gt/gt livers associated with only a few lipogenic mRNAs and Slc2a2 being downregulated, and conversely with Pparg mRNA upregulation (Fig. 7i). The gene discussed is PPARG; the disease is steatosis.